Epocrates Drug Updates - Editor's Pick

July 24, 2014
Zontivity (Oral PAR-1 Inhibitor) Approved for Thrombotic Cardiovascular Events

The FDA recently approved Zontivity (vorapaxar), a once-daily, first-in-class protease-activated receptor-1 (PAR-1) antagonist for the prevention of heart attack and stroke in patients with peripheral arterial disease or a history of myocardial infarction.

Zontivity (Oral PAR-1 Inhibitor) Approved for Thrombotic Cardiovascular Events

Recent Updates

July 17, 2014
Dalvance Approved for Acute Bacterial Skin and Skin Structure Infections in Adults
The FDA recently approved Dalvance (dalbavancin), a new lipoglycopeptide antibacterial for skin and skin structure infections caused by certain gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Dalvance is available as an IV infusion, and is given once weekly for 2 consecutive weeks.
Dalvance Approved for Acute Bacterial Skin and Skin Structure Infections in Adults

July 10, 2014
FDA MedWatch Safety Alert for Docetaxel
The FDA recently warned that docetaxel products contain ethanol (alcohol), potentially causing patients to feel intoxicated during and after treatment. Providers should consider the ethanol content when prescribing or administering docetaxel, particularly in patients in whom alcohol intake should be avoided or minimized, and when used with concomitant medications.
FDA MedWatch Safety Alert for Docetaxel

July 3, 2014
Sivextro Approved for Acute Bacterial Skin and Skin Structure Infections in Adults
The FDA recently approved Sivextro (tedizolid phosphate), a new oxazolidinone antibacterial for skin and skin structure infections caused by certain gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). Sivextro is given once daily for 6 days, and can be administered orally or by IV infusion.
Sivextro Approved for Acute Bacterial Skin and Skin Structure Infections in Adults

June 26, 2014
FDA MedWatch Safety Alert for Testosterone Products
The FDA recently issued a new warning that testosterone products may increase the risk of venous thromboembolism, including DVT and PE. This adverse reaction was reported in post-marketing studies and is unrelated to polycythemia. The warning is not associated with the FDA’s current investigation about cardiovascular event risk in patients taking testosterone products.
FDA MedWatch Safety Alert for Testosterone Products

June 5, 2014
Nexium 24HR Approved for OTC Use
The FDA has approved nonprescription Nexium 24HR (esomeprazole) for the treatment of frequent heartburn in adults. Nexium 24HR is available as 20 mg delayed-release capsules. Nexium 20 mg and 40 mg delayed-release capsules will continue to be available by prescription.
Nexium 24HR Approved for OTC Use

New Drug Monographs

What is an RSS Feed?

From Wikipedia: "RSS is a simple XML-based system that allows users to subscribe to their favorite websites. Using RSS, webmasters can put their content into a standardized format, which can be viewed and organized through RSS-aware software or automatically conveyed as new content on another website."

email Subscribe by email

Enter your email address:


   Cancel

Delivered by FeedBurner